Background Down syndrome patients are characterized by early progression of pulmonary vascular obstructive disease because of insufficient thickness of the pulmonary arterial media. For those with congenital heart disease (CHD) associated with pulmonary hypertension (PH), a 2-stage procedure of pulmonary artery banding (PAB) and then intracardiac repair (ICR) in early infancy is performed to prevent such pulmonary vascular diseases in early infancy.
ntracardiac repair (ICR) undertaken in early infancy for patients with congenital heart disease (CHD) associated with pulmonary hypertension (PH) may result in death despite the use of high-concentration oxygen and nitrogen monoxide (NO) for postoperative PH and respiratory complications, such as interstitial pneumonia-like disease caused by long-term respiratory care. In particular, Down syndrome patients are characterized by early progression of pulmonary vascular obstructive disease (PVOD) 1, 2, 3 because of insufficient thickness of pulmonary arterial media. 4 It has been reported that a 3-month-old Down syndrome patient with absolute operative contraindication died shortly after ICR and another 2 patients who were aged 1 month and 4 months, respectively, and diagnosed as inoperable because of extremely thickened media of the small pulmonary arteries 3 died within 15 days after ICR. 5, 6 For Down syndrome patients with CHD and associated PH, [7] [8] [9] it has been our policy since January 2000 to perform a 2-stage procedure, pulmonary artery banding (PAB) followed by ICR, in early infancy in early infancy to prevent such pulmonary vascular disease. Furthermore, Down syndrome patients often have complications of pulmonary diseases, such as interstitial emphysema or peripheral airway dilatation, during and after surgery, [10] [11] [12] which is attributable to congenital alveolar hypoplasia. 12 In the present study, we retrospectively evaluated whether this therapeutic strategy can prevent progression of not only pulmonary vascular disease but also pulmonary diseases in general.
Methods
The subjects were 16 patients with Down syndrome (Table 1) , of whom 7 patients had atrioventricular septal defect (AVSD) (and 2 of them also had patent ductus arteriosus (PDA)), and 9 patients had ventricular septal defect (VSD) (of whom 4 patients also had PDA). PAB was planned to be performed in early infancy (within 2 months after birth 13 in principle), and ICR approximately 1 year later. Most of the patients underwent lung biopsy during both PAB and ICR, but some who underwent biopsy only during PAB were also included in the study. Written informed consent was obtained when lung biopsy was performed. The lung specimens were taken from the right middle lobe.
The efficacy of the 2-stage procedure was retrospectively examined with reference to pulmonary vascular disease in particular and pulmonary diseases in general. Pulmonary vascular disease was evaluated according to the index of pulmonary vascular disease of Yamaki et al 14, 15 and the subsequent definition of advanced PVOD. The following parameters were compared between patients with and without PVOD: pulmonary-to-systemic flow ratio (Qp/Qs) and pulmonary-to-systemic pressure ratio (Pp/Ps) from the data obtained during cardiac catheterization performed under continuous sedation before PAB and before ICR, and the cardiothoracic ratio (CTR) on chest X-ray taken before PAB (Table 2) . Further, changes in pulmonary diseases ob-served at the time of PAB and ICR were also examined (Table 3) .
PVOD was defined as either of the following irreversible changes.
1. Extremely thickened media of the small pulmonary artery (ie, thickness of the media is equal to or exceeds the diameter of the vascular lumen 3 ).
2. Intimal fibrous thickening 1 (ie, >grade 3 on the HeathEdwards classification 2 ).
The pulmonary diseases investigated in the lung biopsies taken during PAB and ICR were alveolar septitis, lymphangiectasia, microatelectasis, 16 bronchitis obliterans, interstitial emphysema, alveolar hypoplasia, and dilatation of peripheral airways.
Between PAB and ICR, echocardiography was performed to evaluate pulmonary flow velocity across the band.
Differences between data were analyzed using the unpaired t-test. For the index of pulmonary vascular disease, a nonparametric statistical analysis was performed using the Mann-Whitney U-test. For the change in the index of pulmonary vascular disease and the grade of alveolar septitis at PAB and at ICR, a nonparametric statistical analysis was performed using the Wilcoxon rank test.
Results
All AVSD patients had 1 lung biopsy either before PAB or before ICR (cases 3-6). All VSD patients had 2 lung biopsies (ie, before PAB and ICR). The median and 95th percentiles of the index of pulmonary vascular disease were 1.2 and 1.4, respectively (n=16), at PAB, and 1.0 and 1.3, respectively, at ICR (n=12; p=0.0469) ( Table 1 ). In the lung biopsies at PAB, the index of pulmonary vascular disease was less than 1.4 in all patients, which classified them as operable on the basis of previous studies. 17, 18 Five patients (3 AVSD cases (1, 4, 6), 2 VSD cases (13, 14) ) had PVOD. All AVSD patients with PVOD underwent PAB when they were older than 1.5 months, whereas all VSD patients with PVOD underwent PAB when they were older than 2 months. Two patients (cases 1, 14) showed change 1, and 3 (cases 4, 6, 13) showed change 2 ( Table 1 ). All of the latter patients also showed intimal fibrous thickening at ICR. One of the 2 patients having change 1 (case 14) did not show a condition similar to change 1 at ICR, and the other patient (case 1) did not undergo lung biopsy at ICR. However, these 2 patients had less than 7% of the small pulmonary arteries showing extremely thickened media 3 at PAB. There were no patients with complete obstruction of the small pulmonary arterial lumina and atrophy of peripheral arterial media 5 at PAB.
The age at PAB was 2.48±1.22 (mean ± standard deviation) months and body weight (BW) at PAB was 3.75± 0.92 kg. The age at ICR was 13.82±3.09 months and BW was 6.47±0.88 kg, which was significantly increased compared with that at PAB (p<0.0001) ( Table 1) .
Chest X-rays revealed that the CTR before PAB was 0.57±0.03. Cardiac catheterization tests before PAB revealed that the Qp/Qs was 1.74±0.80 and Pp/Ps was 0.92± 0.05, which suggested that the PH might be the result of elevated pulmonary vascular resistance. 19, 20 Cardiac catheterization tests before ICR showed that the Qp/Qs was 1.09±0.28 and Pp/Ps was 0.50±0.12. The values of Qp/Qs, Pp/Ps, and CTR before PAB were not significantly different between the patients with and without PVOD within each of the AVSD and VSD groups ( Table 2) .
There was no significant differences between the with and without PVOD groups in the age at PAB ( Table 4 ). The index of pulmonary vascular disease was significantly higher at PAB for patients in the PVOD group than in patients without PVOD (p=0.0235), but there was no significant difference in the index of pulmonary vascular disease at ICR.
No significant difference in the age at PAB was observed between the AVSD patients with and without PVOD ( Table 5 ). The index of pulmonary vascular disease at PAB was marginally higher in patients with PVOD than in patients without PVOD (p=0.0518), but there was no significant difference in the index of pulmonary vascular disease at ICR. There was no significant difference between the VSD patients with and without PVOD in the index of pulmonary vascular disease at PAB and ICR.
In 9 of 16 patients with mild (grade 2) alveolar septitis 12 at PAB, there was an improvement at ICR (p=0.0431) ( Table 3) . One AVSD patient had bronchitis obliterans, 3 (1 AVSD patient, 2 VSD patients) had lymphangiectasia, and 1 VSD patient had microatelectasis. 5 of these 6 patients with major pulmonary disease at PAB had significantly improved at ICR (lung biopsy was not performed at ICR in case 7). Advanced alveolar hypoplasia characteristic of Down syndrome 12 was observed in only 2 AVSD patients (cases 5, 7), and 1 patient (case 7) with lymphangiectasia already had mild (grade 2) interstitial emphysema at PAB. In the lung biopsies taken before ICR, 1 AVSD patient (case 3) had severe lymphangiectasia, 1 VSD patient (case 11) had microatelectasis, and 1 VSD patient (case 15) had interstitial emphysema that had worsened from being normal at PAB to severe (grade 4).
The 6 patients with major pulmonary disease at PAB comprised 3 AVSD patients (cases 5-7) and 3 VSD patients (cases 9, 12, 13). PVOD was observed in 2 of them (1 AVSD patient with bronchitis obliterans (case 6), 1 VSD patient (case 13) with lymphangiectasia).
Left phrenic nerve paralysis occurred in 3 patients (18.75%) as a complication of the PAB procedure. All cases improved spontaneously over several months. Other major complications such as pulmonary hemorrhage or pneumothorax did not occur and the mortality was zero. However, the mortality rate after ICR was 12.5%, as 2 patients (cases 9, 12) died on the 4th and 35th postoperative day from postoperative infection.
During the follow-up after PAB, most patients were administered digoxin and diuretic but not vasodilators.
Discussion
In this study, the efficacy of the 2-stage procedure of PAB and then ICR to prevent progression of pulmonary vascular disease [7] [8] [9] was proved by performing lung biopsies before each stage. When AVSD and VSD and/or PDA are complicated by early infantile PH, surgical intervention should be performed at an early stage. 17, [21] [22] [23] In Down syndrome patients, in particular, the prognosis largely depends on risk factors associated with PH, 19, 20 such as alveolar hypoplasia 12 and insufficient media thickening 7 in the pulmonary vascular system, which develops into pulmonary vascular disease at an early stage.
In the present study PAB was planned to be performed in early infancy (within 2 months after birth in principle) because in Down syndrome patients with AVSD, PVOD can occur within a few months and they might become inoperable. 5 The histopathologic finding is extremely thickened media of small pulmonary arteries, but if less than 7% of the small pulmonary arteries are affected, early surgical repair is likely to be effective 3 in preventing progression of pulmonary vascular disease. However, some of the present patients were diagnosed with heart disease after 2 months old, so they underwent the procedure at a later age. The highest index of pulmonary vascular disease at PAB was 1.4, which was lower than that suggested by Yamaki et al as an indication for ICR in cases of AVSD 17 and VSD. 18 In patients with PVOD, PAB was performed at 1.5 months or 2 months after birth in cases of AVSD and VSD, respectively, which means that PAB should be performed within 2 months after birth before the pulmonary vascular disease progresses.
Improvement of the pulmonary vascular disease in particular and pulmonary diseases in general were brought about by PAB, which improves reversible intimal thickening. 15 The index of pulmonary vascular disease significantly decreased between PAB and ICR (p=0.0469). It improved at ICR in patients with PVOD, and also tended to improve at ICR in the AVSD patients with PVOD. These findings support the effectiveness of PAB in the PVOD group, especially in AVSD patients with PVOD. Furthermore, PAB improves pulmonary diseases.
Of the major pulmonary diseases evaluated in the present study, alveolar septitis, microatelectasis, and bronchitis obliterans are considered to cause anoxemia, and lymphangiectasia is considered to lead to pulmonary emphysema due to elevated airway pressures. 12 When there are other conditions characteristic of Down syndrome, such as lung tissue hypoplasia, 12 the elevated intrapulmonary pressure caused by postoperative respiratory care or high-concentration oxygen and NO inhalation to control PH worsens the postoperative pulmonary diseases, leading to an increase in mortality. In the present study, alveolar septitis was mild (grade 2) at PAB and had improved at ICR in 6 patients.
Conditions similar to major pulmonary diseases at PAB were not observed at ICR, which indicates that PAB prevents the progress of pulmonary diseases. On the other hand, 3 patients (cases 3, 11, 15) had major pulmonary disease in the lung biopsy at ICR, and the index of pulmonary vascular disease had increased significantly from 1.2 at PAB to 1.3 at ICR in 1 AVSD patient with lymphangiectasia (case 3). This was the only patient in whom the index of pulmonary vascular disease increased after PAB. In this case the pressure difference across the band measured by echocardiography was small during ambulatory follow-up, which suggests that the PH was persistent. Therefore, we decided to perform ICR at 4.5 months after PAB, because we judged the efficacy of PAB was low, and the postoperative course was uneventful. In 1 VSD patient with microatelectasis (case 11), part of the condition was an organic state that we attributed to microatelectasis already existing at PAB.
There might be a causal relationship between PVOD and severe pulmonary diseases because our results showed that PVOD was observed in 2 (cases 6, 13) of the 6 (33.3%) patients with severe pulmonary diseases at PAB. This suggests that Down syndrome patients with AVSD or VSD who undergo PAB after 1.5 months or 2 months after birth, respectively, have an increased likelihood of PVOD or severe pulmonary diseases affecting the postoperative prognosis. However, because there was no significant difference in the parameters before PAB, the development of PVOD could not be predicted.
The results of lung biopsy at PAB and ICR supported the timing of PAB and that ICR as the second stage could be performed after the patients have gained weight. The findings of lung biopsy at PAB showed that the index of pulmonary vascular disease was an operative indication, and none of the patients was diagnosed as inoperable. Pulmonary vascular disease had not progressed, so either ICR or PAB could be performed. According to the growth curve of Down syndrome children, the BW at ICR was less than -2SD of the mean BW at the same time, but significant weight gain occurred in comparison with the BW at PAB. The results of lung biopsy at ICR showed halted progression of pulmonary vascular disease or improvement of pulmonary vascular conditions. There were no patients with complete obstruction of small pulmonary arterial lumina and atrophy of peripheral arterial media in the lung specimens taken at the time of ICR. These histopathologic changes should be considered as absolute operative contraindications. 5 Furthermore, the findings of lung biopsy at ICR showed improvement of pulmonary diseases, and hence our 2-stage procedure appears to be an effective strategy. Although 2 patients (cases 9, 12) died of infection after ICR, the absence of mortality after PAB indicates it at lease is a safe procedure.
As part of the clinical management from the first stage PAB to the second stage ICR, echocardiography was performed to evaluate pulmonary flow velocity across the band. When the pressure difference across the band was small or patients showed hypoxia after PAB, we sometimes used short-term oxygen inhalation to dilate the pulmonary vascular bed. However, if the pulmonary flow velocity across the band did not accelerate despite oxygenation, we considered that the PH was persistent and elected to perform ICR earlier than scheduled.
It is very difficult to judge which of the following surgical procedures is safer for Down syndrome patients with CHD: the 2-stage procedure consisting of PAB, which is a palliative operation, and then ICR; or a 1-stage ICR procedure. We do not suggest that PAB should be performed in all Down syndrome patients with CHD and PH. All Down syndrome patients with CHD should be evaluated for pulmonary diseases. Therefore, particularly for Down syndrome patients with CHD and PH who show hypoxemia with abnormal chest X-ray before surgical intervention, the surgeon should consider PAB as the first choice because of the suspected existence of PVOD in such patients.
We conclude that our 2-stage procedure was an effective treatment strategy for Down syndrome patients with CHD and PH.
